216 related articles for article (PubMed ID: 31959533)
1. Stereotactic Body Radiation Therapy for Extracranial Oligometastatic Non-small-cell Lung Cancer: A Systematic Review.
Tsao MN; Ven LI'; Cheung P; Poon I; Ung Y; Louie AV
Clin Lung Cancer; 2020 Mar; 21(2):95-105.e1. PubMed ID: 31959533
[TBL] [Abstract][Full Text] [Related]
2. Phase II study of stereotactic body radiotherapy to primary tumor and metastatic locations in oligometastatic nonsmall-cell lung cancer patients.
Collen C; Christian N; Schallier D; Meysman M; Duchateau M; Storme G; De Ridder M
Ann Oncol; 2014 Oct; 25(10):1954-1959. PubMed ID: 25114022
[TBL] [Abstract][Full Text] [Related]
3. Stereotactic body radiotherapy improves the survival of patients with oligometastatic non-small cell lung cancer.
Ouyang W; Yu J; Nuerjiang S; Li Z; Wang D; Wang X; Zhang J; Xie C
Cancer Med; 2019 Aug; 8(10):4605-4614. PubMed ID: 31245933
[TBL] [Abstract][Full Text] [Related]
4. The role of stereotactic ablative radiotherapy (SBRT) in the management of oligometastatic non small cell lung cancer.
Guerrero E; Ahmed M
Lung Cancer; 2016 Feb; 92():22-8. PubMed ID: 26775592
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of extracranial stereotactic body radiation therapy (SBRT) added to standard treatment in patients with solid tumors (breast, prostate and non-small cell lung cancer) with up to 3 bone-only metastases: study protocol for a randomised phase III trial (STEREO-OS).
Thureau S; Marchesi V; Vieillard MH; Perrier L; Lisbona A; Leheurteur M; Tredaniel J; Culine S; Dubray B; Bonnet N; Asselain B; Salleron J; Faivre JC
BMC Cancer; 2021 Feb; 21(1):117. PubMed ID: 33541288
[TBL] [Abstract][Full Text] [Related]
6. A Review of Stereotactic Body Radiation Therapy in the Management of Oligometastatic Prostate Cancer.
Zhang B; Leech M
Anticancer Res; 2020 May; 40(5):2419-2428. PubMed ID: 32366385
[TBL] [Abstract][Full Text] [Related]
7. Is there an oligometastatic state in non-small cell lung cancer? A systematic review of the literature.
Ashworth A; Rodrigues G; Boldt G; Palma D
Lung Cancer; 2013 Nov; 82(2):197-203. PubMed ID: 24051084
[TBL] [Abstract][Full Text] [Related]
8. Stereotactic Ablative Body Radiotherapy (SABR) in Pulmonary Oligometastatic/Oligorecurrent Non-small Cell Lung Cancer Patients: A New Therapeutic Approach.
Agolli L; Valeriani M; Nicosia L; Bracci S; De Sanctis V; Minniti G; Enrici RM; Osti MF
Anticancer Res; 2015 Nov; 35(11):6239-45. PubMed ID: 26504057
[TBL] [Abstract][Full Text] [Related]
9. Radiosurgery and fractionated stereotactic radiotherapy in oligometastatic/oligoprogressive non-small cell lung cancer patients: Results of a multi-institutional series of 198 patients treated with "curative" intent.
Buglione M; Jereczek-Fossa BA; Bonù ML; Franceschini D; Fodor A; Zanetti IB; Gerardi MA; Borghetti P; Tomasini D; Di Muzio NG; Oneta O; Scorsetti M; Franzese C; Romanelli P; Catalano G; Dell'Oca I; Beltramo G; Ivaldi GB; Laudati A; Magrini SM; Antognoni P;
Lung Cancer; 2020 Mar; 141():1-8. PubMed ID: 31926440
[TBL] [Abstract][Full Text] [Related]
10. Low-dose hilar and mediastinal stereotactic body radiation therapy for non-small cell lung cancer: Analysis of outcomes in patients receiving one or multiple courses of treatment.
Kowalchuk RO; Waters MR; Richardson M; Spencer K; Larner JM; Kersh CR
Thorac Cancer; 2020 Jul; 11(7):2005-2013. PubMed ID: 32469465
[TBL] [Abstract][Full Text] [Related]
11. Curative treatment of Stage I non-small-cell lung cancer in patients with severe COPD: stereotactic radiotherapy outcomes and systematic review.
Palma D; Lagerwaard F; Rodrigues G; Haasbeek C; Senan S
Int J Radiat Oncol Biol Phys; 2012 Mar; 82(3):1149-56. PubMed ID: 21640513
[TBL] [Abstract][Full Text] [Related]
12. Ablative Therapy for Oligometastatic Non-Small Cell Lung Cancer.
Juan O; Popat S
Clin Lung Cancer; 2017 Nov; 18(6):595-606. PubMed ID: 28377206
[TBL] [Abstract][Full Text] [Related]
13. Long-term Follow-up and Patterns of Recurrence of Patients With Oligometastatic NSCLC Treated With Pulmonary SBRT.
Hörner-Rieber J; Bernhardt D; Blanck O; Duma M; Eich HT; Gerum S; Gkika E; Hass P; Henkenberens C; Herold HU; Hildebrandt G; Imhoff D; Kahl H; Janssen S; Jurianz K; Krempien R; Lautenschläger SF; Lohaus F; Mueller AC; Petersen C; Sackerer I; Scafa D; Schrade E; Uhlmann L; Wittig A; Guckenberger M
Clin Lung Cancer; 2019 Nov; 20(6):e667-e677. PubMed ID: 31327644
[TBL] [Abstract][Full Text] [Related]
14. Comparison of outcomes following stereotactic body radiotherapy for non-small cell lung cancer in patients with and without pathological confirmation.
Haidar YM; Rahn DA; Nath S; Song W; Bazhenova L; Makani S; Fuster MM; Sandhu AP
Ther Adv Respir Dis; 2014 Feb; 8(1):3-12. PubMed ID: 24334338
[TBL] [Abstract][Full Text] [Related]
15. Canadian Phase III Randomized Trial of Stereotactic Body Radiotherapy Versus Conventionally Hypofractionated Radiotherapy for Stage I, Medically Inoperable Non-Small-Cell Lung Cancer - Rationale and Protocol Design for the Ontario Clinical Oncology Group (OCOG)-LUSTRE Trial.
Swaminath A; Wierzbicki M; Parpia S; Wright JR; Tsakiridis TK; Okawara GS; Kundapur V; Bujold A; Ahmed N; Hirmiz K; Kurien E; Filion E; Gabos Z; Faria S; Louie AV; Owen T; Wai E; Ramchandar K; Chan EK; Julian J; Cline K; Whelan TJ
Clin Lung Cancer; 2017 Mar; 18(2):250-254. PubMed ID: 27876603
[TBL] [Abstract][Full Text] [Related]
16. Stereotactic body radiotherapy for centrally located early-stage non-small cell lung cancer or lung metastases from the RSSearch(®) patient registry.
Davis JN; Medbery C; Sharma S; Pablo J; Kimsey F; Perry D; Muacevic A; Mahadevan A
Radiat Oncol; 2015 May; 10():113. PubMed ID: 25975848
[TBL] [Abstract][Full Text] [Related]
17. Combining Dual Checkpoint Immunotherapy with Ablative Radiation to All Sites of Oligometastatic Non-Small Cell Lung Cancer: Toxicity and Efficacy Results of a Phase 1b Trial.
Bassetti MF; Morris BA; Sethakorn N; Lang JM; Schehr JL; Zhao SG; Morris ZS; Buehler D; Eickhoff JC; Harari PM; Traynor AM; Campbell TC; Baschnagel AM; Leal TA
Int J Radiat Oncol Biol Phys; 2024 Apr; 118(5):1481-1489. PubMed ID: 38072321
[TBL] [Abstract][Full Text] [Related]
18. Multi-institutional analysis of stereotactic body radiation therapy for operable early-stage non-small cell lung carcinoma.
Kann BH; Verma V; Stahl JM; Ross R; Dosoretz AP; Shafman TD; Gross CP; Park HS; Yu JB; Decker RH
Radiother Oncol; 2019 May; 134():44-49. PubMed ID: 31005223
[TBL] [Abstract][Full Text] [Related]
19. A Contemporary Update on the Role of Stereotactic Body Radiation Therapy (SBRT) for Liver Metastases in the Evolving Landscape of Oligometastatic Disease Management.
Robin TP; Raben D; Schefter TE
Semin Radiat Oncol; 2018 Oct; 28(4):288-294. PubMed ID: 30309639
[TBL] [Abstract][Full Text] [Related]
20. Stereotactic Body Radiation Therapy for Stage I Non-Small Cell Lung Cancer.
Aridgides P; Bogart J
Thorac Surg Clin; 2016 Aug; 26(3):261-9. PubMed ID: 27427521
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
